Related Experiment Video

Updated: Jun 3, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

The role of MAPK pathway in bone and soft tissue tumors

Kanji Sasaki1, Toshiaki Hitora, Osamu Nakamura

  • 1Department of Orthopaedic Surgery, Kagawa University, Miki-cho, Kita-gun, Kagawa 761-0793, Japan. sasakan1@yahoo.co.jp

Anticancer Research
|March 8, 2011
PubMed
Abstract

Insights

Mitogen-activated protein kinase (MAPK) signaling is active in bone cancers like osteosarcoma. Inhibiting this pathway with U0126 significantly reduced cancer cell proliferation, suggesting a therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • Mitogen-activated protein kinase (MAPK) signaling pathways regulate critical cellular processes, including proliferation.
  • Dysregulation of MAPK signaling is implicated in the development and progression of various cancers.
  • Osteosarcoma (OS) and malignant fibrous histiocytoma (MFH) are aggressive bone malignancies with limited treatment options.

Purpose of the Study:

  • To investigate the expression and role of MAPK signaling components in OS and MFH.
  • To determine if inhibiting MAPK signaling affects the proliferation of OS and MFH cells.

Main Methods:

  • Assessed gene and protein expression of RAF1 and MEK1/2 in human sarcoma cell lines and OS specimens using RT-PCR and immunohistochemistry.
  • Utilized the MEK inhibitor U0126 in cell proliferation assays.
  • Monitored downstream signaling, including p-ERK and p-MEK, following U0126 treatment.

Main Results:

  • RAF1 and MEK1/2 were expressed at both mRNA and protein levels in all tested cell lines and OS specimens.
  • Treatment with U0126 demonstrated dose- and time-dependent inhibition of cell proliferation.
  • U0126 suppressed p-ERK expression, confirming MAPK pathway blockade, while promoting p-MEK.

Conclusions:

  • MAPK signaling is a viable target in OS and MFH.
  • Selective MAPK inhibitors like U0126 show potential for treating bone and soft tissue sarcomas.
  • Targeting MAPK signaling may offer a novel therapeutic strategy for these malignancies.

More Related Videos

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells11:15

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

Published on: May 6, 2018

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...